Metabolic Syndrome — Causes, Symptoms & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Metabolic syndrome (MetS) is a cluster of interrelated cardiometabolic risk factors that co-occur more frequently than expected by chance, sharing the common underlying pathophysiology of insulin resistance and visceral (central) adiposity. The joint IDF/AHA/NHLBI 2009 consensus definition requires any 3 of 5 criteria: (1) waist circumference above 102 cm in men / 88 cm in women (or ethnic-specific thresholds — lower in South Asians and East Asians); (2) fasting triglycerides 1.7 mmol/L (150 mg/dL) or above; (3) HDL-cholesterol below 1.0 mmol/L (40 mg/dL) in men / below 1.3 mmol/L (50 mg/dL) in women; (4) blood pressure 130/85 mmHg or above or on antihypertensive treatment; (5) fasting glucose 5.6 mmol/L (100 mg/dL) or above or on glucose-lowering treatment. MetS affects approximately 25% of adults globally — an estimated 1 billion people — and is rising in parallel with global obesity rates. It confers a 3-fold increased risk of cardiovascular disease, a 5-fold increased risk of type 2 diabetes, and increased risk of non-alcoholic fatty liver disease, polycystic ovary syndrome, certain cancers, and obstructive sleep apnoea.

Insulin resistance is the central pathological mechanism: visceral (intra-abdominal) adipose tissue is metabolically highly active — it releases free fatty acids, proinflammatory adipokines (TNF-alpha, IL-6, resistin), and reduced adiponectin, impairing insulin signalling in liver (increased hepatic glucose output — raising fasting glucose), muscle (reduced glucose uptake), and vasculature (endothelial dysfunction, hypertension). Hyperinsulinaemia (compensatory from insulin resistance) promotes sodium retention (hypertension), triglyceride synthesis (hypertriglyceridaemia), and sympathetic nervous system activation. Primary risk factors: central obesity (visceral adiposity — apple-shaped body fat distribution is far more metabolically harmful than peripheral/gluteofemoral obesity), physical inactivity, high saturated fat and refined carbohydrate diet, and genetic predisposition. Secondary contributing factors: age (insulin sensitivity declines with age), postmenopausal state (oestrogen decline redistributes fat centrally), ethnicity (South Asians and East Asians develop MetS at lower BMI and waist circumference thresholds), sleep disorders (obstructive sleep apnoea — intermittent hypoxia and cortisol dysregulation), and medications (glucocorticoids, antipsychotics — olanzapine, clozapine — cause weight gain and insulin resistance).

Metabolic syndrome has no pathognomonic symptoms — it is a collection of clinical measurements and laboratory findings rather than a symptomatic diagnosis. Many patients are asymptomatic until complications develop. Physical signs on examination: increased waist circumference (central adiposity — assessed by measuring waist at the midpoint between the iliac crest and the lowest rib), elevated blood pressure, and in some — acanthosis nigricans (hyperpigmented velvety plaques in skin folds — axillae, nape of neck, groin — a cutaneous sign of hyperinsulinaemia), and skin tags (acrochordons). Symptoms from established complications: fatigue and polyuria/polydipsia (if overt type 2 diabetes has developed), shortness of breath on exertion (heart failure or coronary artery disease — cardiovascular complications of MetS), right upper quadrant discomfort or fatigue (MASLD — non-alcoholic fatty liver disease, now renamed MASLD — metabolic dysfunction-associated steatotic liver disease), and symptoms of obstructive sleep apnoea (snoring, daytime somnolence, morning headaches). In women, irregular periods, hirsutism, and infertility (PCOS — polycystic ovary syndrome is strongly associated with insulin resistance and MetS).

Metabolic syndrome is diagnosed by clinical measurement and laboratory testing. Joint IDF/AHA/NHLBI 2009 harmonised criteria (any 3 of 5): waist circumference (measured at the umbilicus or mid-point between lowest rib and iliac crest — population-specific cut-points), blood pressure (clinic BP or antihypertensive drug use), fasting plasma glucose (below 5.6 mmol/L normal; 5.6-6.9 mmol/L impaired fasting glucose; above 7.0 mmol/L diabetes) or on antidiabetic treatment, fasting triglycerides (below 1.7 mmol/L normal) or on fibrate/nicotinic acid treatment, and HDL-cholesterol (below 1.0 mmol/L in men; below 1.3 mmol/L in women) or on HDL-raising treatment. Additional investigations: HbA1c (glycated haemoglobin — reflects 3-month average glucose; 48 mmol/mol or above = diabetes; 42-47 mmol/mol = prediabetes); full lipid profile (LDL-cholesterol, total cholesterol, non-HDL cholesterol); liver function tests, GGT and alanine aminotransferase (elevated in MASLD); renal function; urine albumin-to-creatinine ratio (ACR — early diabetic nephropathy marker); liver ultrasound if MASLD suspected (bright liver = steatosis); FibroScan (liver elastography) if significant fibrosis suspected. HOMA-IR (homeostatic model assessment of insulin resistance = fasting insulin × fasting glucose / 22.5 — not routinely measured but confirms insulin resistance).

Lifestyle modification is the cornerstone of metabolic syndrome management — addressing all components simultaneously. Weight loss: 5-10% weight loss significantly improves all five MetS components — reduces visceral fat, lowers fasting glucose, triglycerides, and blood pressure, and increases HDL. Mediterranean diet (high in vegetables, fruit, legumes, whole grains, nuts, olive oil; moderate fish and poultry; low red/processed meat and refined carbohydrates) and DASH diet reduce cardiovascular risk independently of weight loss. Reduce dietary simple sugars and ultra-processed foods (high fructose consumption — particularly from sugar-sweetened beverages — specifically drives hepatic de novo lipogenesis, hypertriglyceridaemia, and visceral fat). Physical activity: 150-300 minutes per week of moderate aerobic exercise improves insulin sensitivity, reduces visceral fat, lowers BP, and raises HDL independently of weight loss; resistance training (2-3 sessions per week) improves insulin sensitivity and reduces visceral adiposity. Sleep optimisation: treating obstructive sleep apnoea (CPAP) reduces metabolic syndrome components. Pharmacological treatment of individual components: Dyslipidaemia: high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg) as first-line for cardiovascular risk reduction; fenofibrate for severe hypertriglyceridaemia (above 5.6 mmol/L — pancreatitis risk); omega-3 fatty acids (icosapent ethyl — REDUCE-IT trial). Hypertension: RAAS blockade (ACE inhibitors — ramipril, lisinopril; or ARBs — losartan, candesartan) are preferred in MetS with insulin resistance — they do not worsen glucose or lipid metabolism (unlike beta-blockers and thiazides). Hyperglycaemia/prediabetes: metformin reduces progression from prediabetes to type 2 diabetes by 31% (DPPOS trial); GLP-1 receptor agonists (semaglutide, liraglutide) cause significant weight loss (10-15%), improve all MetS components, and reduce cardiovascular events in high-risk patients; SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce weight, BP, and cardiovascular and renal events. Bariatric surgery: for morbid obesity (BMI above 40 or above 35 with complications) — achieves metabolic syndrome remission in 70-80% of patients.

Metabolic syndrome significantly increases risk of severe, life-threatening diseases through the combined pathological effects of insulin resistance, central adiposity, dyslipidaemia, and hypertension. Type 2 diabetes mellitus: approximately 50% of people with metabolic syndrome develop T2DM within 10 years without intervention — progressive beta-cell failure superimposed on insulin resistance drives irreversible hyperglycaemia. Cardiovascular disease: MetS carries a 2–3 fold increased risk of myocardial infarction, ischaemic stroke, and cardiovascular death — the clustering of risk factors produces multiplicative rather than additive cardiovascular risk. Non-alcoholic fatty liver disease/metabolic-associated steatotic liver disease (MASLD): affects 70–80% of people with MetS; up to 20% progress to metabolic-associated steatohepatitis (MASH), causing cirrhosis, hepatocellular carcinoma, and liver failure. Chronic kidney disease: hypertension and hyperglycaemia act synergistically to damage glomerular filtration; MetS independently predicts CKD onset and progression. Obstructive sleep apnoea: central obesity narrows the upper airway, and OSA itself worsens insulin resistance in a bidirectional relationship with MetS. Cancer: MetS is associated with increased risk of colorectal, postmenopausal breast, endometrial, pancreatic, liver, and renal cancers — driven by chronic hyperinsulinaemia and systemic inflammation. Polycystic ovary syndrome (PCOS): insulin resistance in women drives androgen excess, anovulation, and menstrual irregularity. Peripheral arterial disease and intermittent claudication are also significantly more prevalent in MetS, and untreated MetS reduces life expectancy by an estimated 5–10 years.

Metabolic syndrome is largely preventable through healthy weight maintenance, physical activity, and diet. Primary prevention: maintain BMI below 25 kg/m2 and waist circumference within target (below 94 cm in men; below 80 cm in women; lower thresholds for South Asian and East Asian populations); eat a Mediterranean or plant-rich diet low in ultra-processed foods and sugar-sweetened beverages; engage in at least 150 minutes of moderate aerobic activity and 2 days of resistance training per week; prioritise 7-9 hours of good quality sleep; avoid or minimise alcohol; do not smoke. Secondary prevention for those with 1-2 criteria: intensive lifestyle intervention delays progression to full MetS and reduces cardiovascular risk — annual monitoring of weight, waist circumference, BP, and fasting lipids and glucose. Public health measures: sugar taxes, food reformulation policies, food labelling, and active travel infrastructure are required to address the societal drivers of metabolic syndrome at population level.

See a GP for a cardiovascular risk assessment and metabolic screening if you are over 40 with any of: central obesity, high blood pressure, family history of type 2 diabetes or cardiovascular disease, or a sedentary lifestyle. The NHS Health Check programme offers free cardiovascular risk assessment every 5 years for people aged 40-74 who are not already known to have a relevant condition — attend when invited. See a GP promptly if you develop: symptoms of hyperglycaemia (excessive thirst, frequent urination, blurred vision — possible new-onset type 2 diabetes), chest pain or breathlessness on exertion (possible coronary artery disease as a complication of untreated MetS), and symptoms of obstructive sleep apnoea. Women with irregular periods, weight gain, and excessive hair growth should be evaluated for PCOS (closely associated with insulin resistance and MetS). People with established MetS should have annual review of blood pressure, HbA1c, lipid profile, and eGFR to monitor for progression and optimise cardiovascular risk reduction.